Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 15/20 | 0.52 |
| ▸ | TUBB | P07437 | 15/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 15/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 15/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 15/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 15/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 15/20 | 0.52 |
| ▸ | TUBB2A | Q13885 | 15/20 | 0.52 |
| ▸ | TUBB8 | Q3ZCM7 | 15/20 | 0.52 |
| ▸ | TUBA3E | Q6PEY2 | 15/20 | 0.52 |
| ▸ | TUBA1A | Q71U36 | 15/20 | 0.52 |
| ▸ | TUBA1C | Q9BQE3 | 15/20 | 0.52 |
| ▸ | TUBB6 | Q9BUF5 | 15/20 | 0.52 |
| ▸ | TUBB2B | Q9BVA1 | 15/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 15/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | SMO | Q99835 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30603593 | 1.00 | TUBB4A (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25478951 | 0.85 | ESR1 (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25478448 | 0.85 | NPSR1 (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL725347 | 0.82 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL29359405 | 0.81 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL724794 | 0.81 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4417618 | 0.81 | PDGFRB (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL722417 | 0.81 | EGFR (0.61) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30017509 | 0.81 | EGFR (0.61) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL26612334 | 0.81 | TUBB4A (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3289876-B1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2022-07-20 | — | — | EP | claimed |
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | claimed |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2019-03-28 | — | — | US | claimed |
| EP-3289876-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2018-03-07 | — | — | EP | claimed |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196632-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3289876-B1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2012027481-A9 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | TUBB4A 2060/4885TUBB 2030/4885TUBA3C 2859/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | TUBB4A 237/4885TUBB 461/4885TUBA3C 625/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885 |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | TUBB3, TUBB1, TUBB | TUBB4A 7/4885TUBB 3/4885TUBA3C 12/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885 |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | TUBB4A 7/4885TUBB 3/4885TUBA3C 4/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885 |
| US-11648236-B2 | Methods of treating coronavirus | TUBB3, TUBB1, TUBB | TUBB4A 7/4885TUBB 3/4885TUBA3C 4/4885 |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | TUBB4A 237/4885TUBB 461/4885TUBA3C 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.